Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 4/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.34 |
| ▸ | MLYCD | O95822 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 2/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13400259 | 1.00 | HDAC6 (0.38) | HDAC6OPRK1OPRD1CTSKAR | |
| SCHEMBL1710752 | 0.87 | BCHE (0.38) | CTSKBCHE | |
| SCHEMBL1725728 | 0.83 | EPHX1 (0.39) | OPRK1OPRD1CTSKBCHE | |
| SCHEMBL1710407 | 0.82 | EPHX1 (0.38) | OPRK1OPRD1CTSKBCHE | |
| SCHEMBL1710635 | 0.82 | HTR2A (0.37) | OPRK1OPRD1CTSKARBCHE | |
| SCHEMBL3387273 | 0.81 | MTNR1A (0.32) | MTNR1AMTNR1B | |
| SCHEMBL1710557 | 0.80 | AR (0.34) | AR | |
| SCHEMBL1710639 | 0.80 | AR (0.34) | AR | |
| SCHEMBL1725082 | 0.80 | MTNR1A (0.33) | MTNR1AMTNR1B | |
| SCHEMBL2207058 | 0.80 | SIRT2 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093865-A1 | SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093865-A1 | SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, MPST, CLN6 | HDAC6 250/4885OPRK1 2942/4885OPRD1 2036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.